Company intelligence / Profile preview

BCAL Diagnostics

Sydney, New South Wales, Australiabcaldiagnostics.com ↗

Ownership: Private
Employees: ~50
Development stage: Commercial

Overview

BCAL Diagnostics has developed BREASTEST plus™, a first-in-class non-invasive blood test designed to complement mammography for breast cancer screening. The test provides additional information for women with dense breast tissue and aims to improve early detection rates. The product has been in development for over a decade and continues to undergo clinical validation. No large-scale commercial launch or pivotal trial results are yet reported.

Therapeutic areas: Oncology
Modalities: Device (blood test)In vitro diagnostic
Industry: Metabolite Diagnostics

Drug pipeline

1 asset

BREASTEST plus

Commercial

Indications: Breast cancer

Partnerships

Clinical partnerships with healthcare providers and clinicians; no major pharma/biotech partnerships disclosed

Beyond the preview

Go deeper on BCAL Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BCAL Diagnostics.

Explore the full profile